Drug Database
PA

pasireotide (Signifor LAR / pasireotide, LAR / pasireotide LAR)

✓ Approved

Novartis AG · SSTR1 · Small Molecule

What is pasireotide?

pasireotide is a small molecule developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or subcutaneous injection.

Drug Profile

Brand NamesSignifor LAR, pasireotide, LAR, pasireotide LAR
CompanyNovartis AG
Drug ClassSmall Molecule, Polypeptide
Molecular TargetSSTR1, SSTR2, SSTR3, SSTR5
RouteInjectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Mechanism of Action

Molecular Targets

pasireotide acts on 4 molecular targets:

SSTR1somatostatin receptor 1 (SS-1-R, SS1-R)
SSTR2somatostatin receptor 2 (SST2)
SSTR3somatostatin receptor 3 (SST3, SS3R)
SSTR5somatostatin receptor 5 (SST5, SS-5-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pasireotide is developed for 11 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Endocrine disordersAcromegaly✓ Approved
Endocrine disordersPituitary-dependent Cushing's syndrome✓ Approved
Endocrine disordersCarcinoid syndromePhase III
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colon cancer recurrentPhase III
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Pituitary tumour benignPhase II

+6 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2026-09-18

Association of SII, LAR, and D-Dimer with In-Hospital Adverse Outcomes in Acute Pulmonary Embolism.

Chen Zixuan Z, Huang Sijia S, Song Yuxiao Y, Gong Wanwei W et al.

ObjectivesTo investigate the prognostic value of the systemic immune-inflammation index (SII), lactate-to-albumin ratio (LAR), and D-dimer for in-hospital adverse outcomes in patients with acute pulmonary embolism (APE).MethodsThis single-center retrospective cohort study screened 248 patients with computed tomography pulmonary angiography-confirmed APE between June 2022 and February 2026; 151 patients were included after 97 exclusions. Predictors were defined using the first measurements obtained within 24 hours after admission and before anticoagulation, thrombolysis, vasopressor therapy, or any related adverse event. The primary outcome was an in-hospital composite of intensive care unit transfer, shock or vasopressor use, cardiopulmonary resuscitation, catheter-based therapy or thrombolysis, and fatal outcome (in-hospital death or withdrawal of life-sustaining treatment after irreversible deterioration). Multiple imputation and logistic regression were used to construct and compare an sPESI model, a biomarker model, and a combined model. Performance was assessed using receiver operating characteristic curves, calibration analysis, bootstrap internal validation, and decision curve analysis.ResultsAmong 151 patients, 37 (24.5%) experienced the composite outcome and 114 did not. SII, LAR, and D-dimer remained associated with the outcome after adjustment for sPESI. Model 2 had an AUC of 0.891, compared with 0.637 for model 1 and 0.661 for ESC risk classification. Adding sPESI or ESC classification to model 2 increased the AUC to 0.912 and 0.900, respectively, without a significant further improvement in discrimination (P=.221 and P=.409). The bootstrap-corrected AUC for model 2 was 0.885, the Brier score was 0.091, and internal decision-curve analysis showed potential net benefit.ConclusionsAdmission SII, LAR, and D-dimer were associated with in-hospital adverse outcomes and remained associated after adjustment for sPESI. The exploratory three-biomarker model may complement sPESI and ESC risk classification, but multicenter external validation is required before clinical application.

PMID 42758097
Read full article →
PubMedThe international journal of medical robotics + computer assisted surgery : MRCAS2026-09-16

Gender-Specific Cancer-Related Survival Analysis of Robotic Versus Laparoscopic Low Anterior Resection for Rectal Adenocarcinoma: A Multicenter Study.

Benlice Cigdem C, Ramoglu Nur N, Bilgin Ismaıl Ahmet IA, Kaya Ayse Gulsah AG et al.

This study compared short- and long-term outcomes of robotic and laparoscopic low anterior resection (LAR) for rectal adenocarcinoma using sex-stratified analyses. Patients who underwent elective robotic or laparoscopic LAR for rectal cancer were included. Prospectively maintained database of outcomes was analysed retrospectively. To minimise selection bias, groups were matched. Of 409 identified patients, 380 met the eligibility criteria (mean age: 61 years, BMI: 26.2 kg/m2). In a matched cohort of males (n = 172) and females (n = 114), robotic surgery was associated with significantly shorter hospital stay (p < 0.01). Harvested lymph nodes, margins, morbidity and local recurrence were comparable in males (p > 0.05). Robotic surgery in females was associated with fewer harvested lymph nodes (p = 0.01). Five-year disease-specific survival rates did not significantly differ between approaches in either gender. Robotics and laparoscopic LAR achieved similar oncologic outcomes. The findings should be interpreted as sex-stratified comparisons rather than evidence of differential effect of surgical approach according to sex.

PMID 42747085
Read full article →
PubMedJournal of clinical medicine2026-09-15

Late-Course Lactate/Albumin Ratio and In-Hospital Mortality in CRRT-Treated Critically Ill Patients: A Retrospective Severity-Adjusted Analysis.

Şenay Hasan H, Orhan Mehmet Kürşad MK, Tutar Mahmut Sami MS, Yıldız Munise M et al.

Background/Objectives: The lactate/albumin ratio (LAR) integrates tissue hypoperfusion and nutritional reserve into a single dimensionless index. As a late-course measurement (last available value before the primary outcome), it may reflect terminal metabolic deterioration rather than early prognostic signal. We examined the association of the final LAR with in-hospital mortality after adjustment for validated severity scores (APACHE II, SOFA) in critically ill patients receiving CRRT, and evaluated its incremental value beyond lactate alone. Methods: A single-centre retrospective observational study was conducted, including 110 adult patients treated with CRRT/CVVHDF at Konya City Hospital (January 2024-January 2026). Multivariable logistic regression was performed across four hierarchically adjusted models. APACHE II was designated the primary adjustment covariate. ROC analyses compared the final LAR with final lactate and albumin alone. Results: In-hospital mortality was 70.9% (78/110); complete paired final lactate and albumin values were available for 109/110 patients (78 non-survivors, 31 survivors). After APACHE II adjustment, each 0.1-unit increase in the late-course LAR remained significantly associated with in-hospital mortality (OR 1.70; 95% CI 1.16-2.49; p = 0.007), a finding replicated in the ICU-stay sensitivity cohort (n = 100, 73 events; OR 1.63; 95% CI 1.09-2.42; p = 0.016). The LAR trajectory (ΔLAR; AUC 0.725) was significantly greater in non-survivors (+0.104 vs. -0.060; p < 0.001); however, ΔLAR did not significantly outperform the lactate trajectory alone (Δlactate; AUC 0.706; p = 0.212), and lost statistical significance after severity-score adjustment. Furthermore, the association was attenuated and non-significant after SOFA adjustment (OR 1.35; p = 0.077), and the final LAR did not provide statistically significant discriminative advantage over lactate alone (AUC 0.768 vs. 0.761; LRT p = 0.435). Conclusions: The late-course LAR remained significantly associated with mortality after APACHE II adjustment. Three qualifications temper this finding: the association was attenuated after SOFA adjustment, the final LAR did not outperform lactate alone, and the measurement design is susceptible to reverse causality. The LAR trajectory (ΔLAR; AUC 0.725) showed comparable discrimination to the final LAR but did not significantly outperform the lactate trajectory alone (Δlactate; AUC 0.706; p = 0.212) and lost statistical significance after severity-score adjustment, so it should likewise be regarded as hypothesis-generating rather than confirmatory; prospective evaluation with time-stamped serial measurements and landmark analyses in multi-centre CRRT cohorts is warranted.

PMID 42739631
Read full article →
PubMedJournal of clinical medicine2026-09-15

Incremental Prognostic Value of Glucose Variability and the Lactate-to-Albumin Ratio Beyond APACHE II After a 48-Hour Landmark in Critically Ill Adults: A Retrospective Cohort Study.

Öner Sait Fatih SF, Şenol Karataş Sevim S, Bulut Oğuz Kağan OK

Background/Objectives: Glucose variability (GV) and the lactate-to-albumin ratio (LAR) have been associated with adverse outcomes in critically ill patients, but their incremental prognostic contribution beyond established severity assessment remains uncertain. This study evaluated the associations of GV and LAR with subsequent mortality and their incremental value beyond APACHE II in a conditional 48 h landmark cohort. Methods: This single-center retrospective cohort study included 384 critically ill adults who were alive and remained in the ICU through 48 h and had sufficient glucose, lactate, and albumin measurements. GV was quantified using the coefficient of variation (CV) from six glucose measurements closest to 0, 8, 16, 24, 32, and 48 h. The primary outcome was all-cause mortality during the 7 days following the 48 h landmark. Firth penalized logistic regression was used for prognostic modeling. Incremental performance was assessed sequentially for APACHE II, APACHE II + LAR, and APACHE II + LAR + GV using discrimination, calibration, Brier score, bootstrap internal validation, and decision-curve analysis. Sensitivity analyses adjusted for mean glycemia and restricted predictor information to the first 24 h. Results: Eighty-eight patients (22.9%) died during the 7-day post-landmark period. APACHE II (OR: 1.19 per point, 95% CI: 1.12-1.27; p < 0.001), LAR (OR: 1.97 per unit, 95% CI: 1.48-2.69; p < 0.001), and GV (OR: 1.07 per 1-percentage-point increase in CV, 95% CI: 1.02-1.11; p = 0.002) were independently associated with mortality. The AUC increased from 0.804 for APACHE II alone to 0.844 after addition of LAR and to 0.857 after further addition of GV. The additional AUC increase attributable to GV after LAR was modest (ΔAUC = 0.013, 95% CI: -0.004 to 0.030; p = 0.145), although model fit and Brier performance improved. The optimism-corrected C-index of the integrated model was 0.851. GV remained independently associated with mortality after adjustment for mean glucose (OR: 1.06, 95% CI: 1.02-1.11; p = 0.002) and in the temporally matched 24 h analysis (OR: 1.05, 95% CI: 1.01-1.09; p = 0.008). Conclusions: Among critically ill adults who survived to a 48 h landmark, LAR and GV provided prognostic information beyond APACHE II. Most of the incremental improvement in discrimination was attributable to LAR, whereas GV provided a smaller additional contribution that remained consistent across sensitivity analyses. These findings support further evaluation of LAR and GV as complementary prognostic markers, but external validation is required before clinical implementation.

PMID 42739928
Read full article →
PubMedMedicine2026-09-15

Prognostic value of the lactate-albumin ratio and development of a nomogram-based prediction model in patients with acute myocardial infarction-associated cardiogenic shock.

Angdembe Roshan R, Wu You Y, Ke Qun Q, Jin Yinsheng Y et al.

Cardiogenic shock (CS) is a serious complication of acute myocardial infarction (AMI), associated with in-hospital mortality rates of more than 40%. There is a lack of accuracy and clinical applicability in the existing risk scores, emphasizing the need for improved prognostic models using novel biomarkers. This study aimed to evaluate the prognostic role of the lactate-to-albumin ratio (LAR) in AMI-CS patients and to construct a nomogram-based model incorporating LAR with conventional clinical indicators. This prospective study enrolled 129 AMI-CS patients admitted to the cardiac care unit of Renmin Hospital (November 2022-December 2024). Patients were divided into survivor (n = 106) and in-hospital mortality (n = 23) groups. Clinical and laboratory data were compared using univariate analysis. Variables with prognostic potential were initially screened using Least Absolute Shrinkage and Selection Operator regression before entering multivariable logistic analysis. A nomogram was constructed using independent predictors and evaluated using receiver operating characteristic-area under the curve (AUC), calibration analysis, Hosmer-Lemeshow testing, and decision curve analysis. LAR, cold and clammy skin, aspartate aminotransferase, C-reactive protein, and left ventricular ejection fraction < 40% emerged as independent predictors of in-hospital mortality. The median (interquartile range) for LAR was significantly higher in the in-hospital mortality group versus the survival group (2.82 [0.93-4.2] vs 0.59 [0.42-1.54]), P = .002. The best cutoff value for LAR was 1.997, with 65% sensitivity and 82% specificity. LAR had an AUC of 0.767, outperforming blood lactate (0.749), and showed strong prognostic value (odds ratio: 1.495, 95% confidence interval: 1.174-1.904, P = .001). The nomogram-based model achieved an AUC of 0.928, outperforming CardShock (0.782), Acute Physiology and Chronic Health Evaluation II (0.727), and blood lactate (0.749). The model demonstrated excellent calibration (mean absolute error: 0.04), and goodness-of-fit was confirmed (Hosmer-Lemeshow P = .648). Decision curve analysis indicated superior clinical usefulness. LAR is a meaningful indicator for early mortality risk in AMI-CS. The proposed nomogram may support faster decision-making and bedside risk evaluation.

PMID 42736724
Read full article →
PubMedAnnals of surgical treatment and research2026-09-15

Learning curve analysis of laparoscopic low anterior resection using the ArtiSential multi-articulating device: a multicenter retrospective cohort study with pooled analysis (STARC trial).

Kim Seijong S, Pyo Dae Hee DH, Lee Jaeim J, Kim Chang Hyun CH et al.

Robotic surgery has shown promising outcomes in colorectal cancer treatment but is limited by its high cost. In response, the ArtiSential system (LivsMed Inc.), an articulated handheld laparoscopic instrument, has emerged as an alternative. This study aimed to assess the learning curve associated with ArtiSential during low anterior resection (LAR) of colorectal cancer. A multicenter retrospective cohort study enrolled 208 patients who underwent LAR with ArtiSential between January 2021 and October 2022. A cumulative sum (CUSUM) analysis was conducted for operation time. Three experienced surgeons, each with over 30 completed ArtiSential-assisted LAR procedures, were included in the analysis. The median operation time was 129 minutes; it was accompanied by minimal blood loss and no open conversions. Pathological analysis revealed favorable outcomes with high-quality total mesorectal excision and a circumferential resection margin. Surgeons A and B followed a conventional 4-stage learning curve, achieving mastery after 25 and 24 cases, respectively. In contrast, surgeon C demonstrated a unique 2-stage learning curve, achieving mastery after 19 cases. The CUSUM analysis suggests a relatively manageable learning curve, with the initial phase being completed after approximately 10 cases and proficiency attained after 20-30 cases. In conclusion, ArtiSential appears to be a promising tool for colorectal surgeons, offering a favorable learning curve and encouraging outcomes in LAR for rectal cancer.

PMID 42741487
Read full article →

+5301 more articles available with a free account

Sign up free to view all articles →

Ask about pasireotide